Creative Biolabs is a world-leading service provider of application-specific antibody development. Here, we introduce our in vitro diagnostic (IVD) antibody development and immunoassay development services targeting myeloperoxidase marker. We are confident that our commitment to science and research will enable us to offer you the best products and services.
Myeloperoxidase (MPO), a protein generated during myeloid differentiation, is a pivotal component of neutrophil azurophilic granules. The mature MPO is a 150-kDa tetramer protein comprised of two light chains and two heavy chains that binds to a prosthetic heme group. MPO comprises a calcium binding site with seven ligands, constituting a pentagonal pyramid conformation. It catalyzes oxidative modifications of lipoproteins, improves bioavailability of nitric oxide, and enhances plaque instability. Meanwhile, MPO has proinflammatory and pro-oxidative properties and has been proven to be related to the development and rupture of atherosclerotic plaques. Its concentration is connected with the degree of endothelial dysfunction. Besides, systemic MPO concentrations have been indicated to offer prognostic information among patients with present acute coronary syndromes (ACS) and chest pain. Moreover, MPO concentrations seem to be highly stable in ethylenediaminetetraacetic acid (EDTA) plasma, and time dependent variation of that was observed after percutaneous coronary intervention (PCI) in patients with MI.
Fig.1 Three-dimensional structure of a myeloperoxidase (MPO) homodimer. MPO is a peroxidase enzyme that is most expressed in neutrophil granulocytes.1
Myeloperoxidase Marker of Myocardial Infarction
MI results in notable mortality and morbidity. Early diagnosis makes clinicians to risk stratify their patients and choose suitable treatment. Currently, biomarkers have been widely exploited to diagnosis, meanwhile, a variety of new markers have been determined to predict outcomes following an acute myocardial infarction (AMI), including MPO. A research indicated that post-ACS MPO levels higher than median suggested future death and MI at one year. It has also been proven that after an AMI, MPO levels reach to the peak early, subsequent reduce over time and do not connect with troponin or the neutrophil count. Besides, two population researches demonstrated that MPO in healthy individuals is correlated to future development of CAD. What's more, in patients with suspected MI, MPO levels above 306.3 pmol/L detected 24 hours after onset of symptoms were independent predictors of 6-month mortality and MACE (major adverse cardiac events), as reported.
IVD Antibody Development Services for MPO Marker
In order to render more precise antibody-based diagnostic tools and assist clinicians in the diagnosis, prognosis, and staging of different diseases and infections, Creative Biolabs provides customized IVD antibody development services to generate high-quality antibodies for diagnostic usage. Besides antibody generation, we also offer antibody conjugation, antibody pairing, and diagnostic immunoassay development services to our clients. For more detailed information, please feel free to contact us or directly send us an inquiry.
Reference
For Research Use Only.
